Eli Lilly and Company (NYSE:LLY) Shares Sold by Wilbanks Smith & Thomas Asset Management LLC

Wilbanks Smith & Thomas Asset Management LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,754 shares of the company’s stock after selling 32 shares during the period. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Eli Lilly and Company were worth $8,601,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $27,000. Legacy Financial Group LLC purchased a new position in Eli Lilly and Company in the third quarter valued at about $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company in the third quarter worth about $36,000. Finally, Family CFO Inc purchased a new position in Eli Lilly and Company in the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Barclays raised their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Truist Financial increased their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $9.07 during trading on Thursday, reaching $767.68. The company had a trading volume of 730,834 shares, compared to its average volume of 3,038,991. Eli Lilly and Company has a one year low of $414.31 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm’s 50 day simple moving average is $762.03 and its two-hundred day simple moving average is $669.96. The company has a market capitalization of $729.42 billion, a PE ratio of 114.40, a PEG ratio of 1.58 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.62 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.